Medtronic executives tout significant firepower for acquisitions as FDA clears MiniMed Go system
At the San Francisco conference, Medtronic executives highlighted the company’s significant firepower for multiple acquisitions as it evaluates portfolio-expanding opportunities. Medtronic secured FDA 510(k) clearance for the MiniMed Go Smart MDI system integrating its InPen pen with Abbott’s Instinct sensor, with U.S. launch planned this spring.
1. Medtronic Reports ‘Significant Firepower’ for Strategic Acquisitions
At the JP Morgan Healthcare Conference in San Francisco on January 12, Medtronic executives confirmed the company holds over $14 billion in available liquidity — combining cash, marketable securities and undrawn credit facilities — positioning it to pursue multiple bolt-on acquisitions across its core businesses. CEO Geoff Martha highlighted that this firepower would be directed toward high-growth segments such as surgical robotics, neuromodulation and spinal implants. Medtronic’s 2025 R&D investment exceeded $2.2 billion, reflecting management’s commitment to internal innovation; executives signaled that targeted acquisitions could accelerate time-to-market for digital surgery platforms and next-generation neuromodulation therapies.
2. Precision Neuroscience™ Partnership to Enhance StealthStation™ Platform
Medtronic announced a collaboration with Precision Neuroscience to integrate the latter’s Layer 7™ cortical interface into Medtronic’s StealthStation™ surgical navigation system. The joint solution is engineered to deliver real-time, high-resolution functional and structural mapping during cranial procedures, potentially reducing intraoperative decision time by 30 percent. Precision Neuroscience CEO Michael Mager noted the integrated system will enter initial clinical validation later this year, with US and EU regulatory submissions planned for mid-2027. Medtronic’s Neuroscience portfolio President Brett Wall emphasized that coupling Precision’s minimally invasive electrodes with StealthStation™ 3D imaging could expand indications for adaptive brain therapies worldwide.
3. Medtronic Diabetes Secures FDA Clearance for MiniMed Go™ Smart MDI System
On January 12, Medtronic Diabetes received US FDA 510(k) clearance for its MiniMed Go™ Smart Multiple Daily Injection system, which integrates the InPen™ smart insulin pen with Abbott’s Instinct continuous glucose monitor via a unified mobile app. Clinical data from 1,852 type 1 diabetes users showed Time in Range improvements from 55.7 percent to 67.2 percent when missed-dose alerts were addressed within an hour, and up to 71.5 percent when corrective boluses were administered promptly. The system is cleared for patients aged 7 and older, with supervised pediatric use down to age 2. Commercial launch is slated for spring 2026 in the United States.